期刊
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
卷 23, 期 6, 页码 521-533出版社
TAYLOR & FRANCIS AS
DOI: 10.1080/14737159.2023.2216386
关键词
Heart failure; Prognosis; Natriuretic peptides; biomarkers; Guiding therapy
类别
Heart failure is a serious health issue with a poor prognosis, and natriuretic peptides have been used extensively for diagnosis and risk stratification in HF.
IntroductionHeart failure (HF) is a dominant health problem with an overall poor prognosis. Natriuretic peptides (NPs) are upregulated in HF as a compensatory mechanism. They have been extensively used for diagnosis and risk stratification.Areas coveredThis review addresses the history and physiology of NPs in order to understand their current role in clinical practice. It further provides a detailed and updated narrative review on the utility of those biomarkers for risk stratification, monitoring, and guiding therapy in HF.Expert opinionNPs show excellent predictive ability in heart failure patients, both in acute and chronic settings. Understanding their pathophysiology and their modifications in specific situations is key for an adequate interpretation in specific clinical scenarios in which their prognostic value may be weaker or less well evaluated. To better promote risk stratification in HF, NPs should be integrated with other predictive tools to develop multiparametric risk models. Both inequalities of access to NPs and evidence caveats and limitations will need to be addressed by future research in the coming years.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据